辅助放疗是治愈乳腺癌的综合性治疗的重要组成部分。我们旨在研究螺旋调强放射治疗在乳腺保留手术后局限性乳腺癌和淋巴结阴性女性患者的长期临床结果。在这项单中心分析中，219名早期乳腺癌（T1/T2）和无淋巴结转移（N0）的女性患者接受了螺旋调强放射治疗，使用了调强放疗技术，分段放射整个乳房。当需要加强照射时，可以使用顺序或同步集成加强技术。回顾性分析局部控制（LC）、转移和生存率、急性毒性、迟发性毒性和继发性恶性肿瘤率。平均随访时间为71个月。5年和8年的总生存率分别为97.7%和92.1%。5年和8年的局部控制率分别为99.5%和98.2%，5年和8年转移自由生存率分别为97.4%和94.3%。 G3分级或雌激素受体阴性的患者结果没有显著差异。79%的患者出现急性红斑（0-2级）和21%的患者出现3级急性红斑。同侧肢体淋巴水肿和肺炎分别发生在6.4%和1.8%的治疗患者中。在随访期间，没有患者发生> 3级毒性，而1.8%的患者在随访期间出现继发性恶性肿瘤。螺旋调强放射治疗表现出良好的长期效果和低毒性率。继发性恶性肿瘤的发生率相对较低，并与放疗的现有数据相关，提示广泛实施螺旋调强放疗技术在乳腺癌患者辅助放疗中的意义。版权所有© 2023 International Institute of Anticancer Research (Dr. George J. Delinasios)。

Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery.In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively.The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up.Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.